PEG

Functionalized von-Hippel-Lindau (VHL) protein ligand for PROTAC research and development; incorporates an E3 ligase ligand plus a PEG1 linker with terminal carboxylic acid ready for conjugation to a target protein ligand. Part of a range of functionalized tool molecules for PROTAC R&D. PROTAC is a registered trademark of Arvinas Operations, Inc., and is used under license.

DSPE-PEG(2000)-amine is a PEGylated derivative of 1,2-distearoyl-sn-glycero-3-PE . It has been used in the synthesis of solid lipid and thermosensitive liposomal nanoparticles for the delivery of anticancer agents.1,2,3DSPE-PEG(2000)-amine has also been used in the synthesis of fluorescein isothiocyanate-loaded mesoporous silica nanoparticles for imaging applications.4It can be conjugated to a variety of functional molecules for improved cellular targeting and uptake of DSPE-PEG(2000)-amine-containing nanoparticles.4,5

Tos-PEG3-CH2COOtBu is a PEG-based linker for PROTACs that joins two essential ligands, facilitating selective protein degradation through the ubiquitin-proteasome system within cells.

NHS-PEG1-SS-PEG1-NHS is a reversible linker used for interacting biomolecules with active small molecules and is effective for linking protein liposomes or nanoparticles (NHS-PEG1-SS-PEG1-NHS).

Thalidomide-O-amido-C3-PEG3-C1-NH2 is a synthesized conjugate compound serving as an E3 ligase ligand-linker, featuring a cereblon ligand based on Thalidomide and a 3-unit PEG linker, specifically designed for use in PROTAC technology.

NH2-PEG2-CH2-Boc is a PEG-based linker for PROTACs, enabling the conjugation of two essential ligands for PROTAC molecule formation. This linker facilitates selective protein degradation by leveraging the ubiquitin-proteasome system within cells.

Pomalidomide-amino-PEG4-NH2 hydrochloride, a synthesized E3 ligase ligand-linker conjugate, incorporates the cereblon ligand derived from Pomalidomide, along with a linker commonly employed in PROTAC technology.

Thalidomide-Piperazine-PEG3-NH2 is a synthesized E3 ligase ligand-linker conjugate that combines a Thalidomide-based cereblon ligand with a linker commonly used in [PROTAC] technology, functioning as an E3 ligase recruiter.

DBCO-PEG4-MMAF is an antibody-drug conjugate (ADC) component that exhibits potent antitumor activity. It combines the tubulin polymerization inhibitor MMAF with a cleavable linker, DBCO-PEG4, to target cancer cells effectively.